Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin

Abstract

To explore if combinations of linezolid (L) with rifampicin (R) are able to restrict Staphylococcus aureus resistance, the enrichment of L- and R-resistant mutants was studied in an in vitro dynamic model. L- and R-resistant mutants were enriched in all single drug treatments. In contrast, L-resistant mutants were not enriched and R-resistant mutants were similar to baseline amounts with only minimal regrowth at the end of the combination treatments. These effects appear to be explained by lowering the mutant prevention concentration (MPC) for L+R combinations (MPC_L+R) compared to the MPCs of L and R alone (MPC_L and MPC_R) and thereby the longer times above MPC_L+R (73–100% of the dosing interval for L and 42–58% for R) compared to the times above MPC_L (0–44%) and MPC_R (0%). These findings provide an opportunity to predict the selection of S. aureus resistance in L+R treatments using MPC_L+Rs.

Keywords:

• Staphylococcus aureus
• Antibiotic combination
• Linezolid
• Rifampicin
• In vitro model